Infectious diseases
Chlamydia: pregnancy changes treatment and follow-up
A familiar seven-day regimen is not a universal answer to chlamydia. Pregnancy changes the recommended medicine and makes a test of cure important. NAAT timing matters because residual nonviable organisms can produce an early positive result.
Sources checked October 7, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Read pregnancy status first
The general adolescent and adult recommendation is doxycycline 100 mg orally twice daily for 7 days. During pregnancy it is azithromycin 1 g orally once, with amoxicillin 500 mg orally three times daily for 7 days as an alternative. These are different branches, not interchangeable preferences.
CDC states that doxycycline is contraindicated in the second and third trimesters because of tooth-discoloration risk. Pregnancy status is a clinical safety fact, not simply a preference for fewer tablets. Neonatal and pediatric infections also have their own regimens.
Keep site and adherence in view
CDC describes better efficacy of doxycycline than azithromycin for rectal chlamydia. For nonpregnant patients, azithromycin is an alternative when multidose adherence is a substantial concern, but posttreatment evaluation may be needed because of lower efficacy at the rectal site.
Preserve the reason for an alternative. Do not claim a single dose is equally effective at every site, or assume that absence of reported receptive anal exposure excludes concurrent rectal infection. Follow the actual diagnostic and clinical assessment.
Write a purpose beside the repeat test
During pregnancy, CDC recommends a test of cure, preferably NAAT, about 4 weeks after treatment completion. Retesting at 3 months checks for repeat infection. Age- and risk-based screening and rescreening can also be needed, so one negative result does not complete the whole pregnancy plan.
For nonpregnant patients, routine test of cure is not advised unless adherence is uncertain, symptoms persist or reinfection is suspected. NAAT less than 4 weeks after completion is not recommended because residual nonviable organisms can lead to false-positive results.
Treat partner care as part of the answer
CDC advises abstaining for 7 days after single-dose therapy or until completion of the seven-day regimen, symptom resolution and partner treatment. A correct prescription does not protect against exposure to an untreated partner. Ask what the partner plan actually is.
Recent partners need evaluation, testing and presumptive treatment under the guideline. Expedited partner therapy depends on applicable law and clinical context. Recognizing a need for partner care is not blanket permission to supply an unscreened partner prescription.
A worked case
A patient at 24 weeks of pregnancy has uncomplicated chlamydia. A draft plan uses doxycycline and a routine NAAT ten days after completion. What needs review?
- Apply the pregnancy recommendation: azithromycin 1 g orally once.
- Use approximately four weeks after completion for the pregnancy test of cure.
- Keep three-month retesting and partner management as separate tasks.
Answer: Pregnancy changes the medicine and follow-up timing.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does every treated nonpregnant adult need routine test of cure?
No. CDC reserves it for concerns such as adherence, persistent symptoms or suspected reinfection.
2. Does a positive NAAT ten days after completion prove failure?
No. Early testing can detect residual nonviable organisms.
3. Does a negative four-week test remove the later reinfection check in pregnancy?
No. Three-month retesting serves a different purpose.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.